A randomized study of coronary artery bypass surgery performed with the Resting Heart™ System utilizing a low vs a standard dosage of heparin

Interact Cardiovasc Thorac Surg. 2012 Nov;15(5):834-9. doi: 10.1093/icvts/ivs345. Epub 2012 Aug 21.

Abstract

Objectives: Allogeneic blood transfusion and reoperation for postoperative bleeding after the coronary artery bypass grafting have a negative impact on the patient outcome. This study aimed at evaluating the effects of reduced doses of heparin and protamine on the patient outcome, using a heparin-coated mini-cardiopulmonary bypass (CPB) system.

Methods: Sixty patients undergoing elective first-time CPB were prospectively randomized either to have a reduced systemic heparinization [activated clotting time (ACT) = 250 s] or to a control group perfused with a full heparin dose (ACT = 420 s). Blood transfusions, ventilation time, early postoperative bleeding, ICU stay, reoperations for bleeding, postoperative cognitive status and the level of mobilization were registered.

Results: Twenty-nine patients were randomized to the control group, 27 patients to the low-dose group and 4 patients were excluded because of protocol violations. Four patients in the control group received a total of 10 units of packed red blood cells, and in the low-dose group, no transfusions were given, P = 0.046. No patient was reoperated because of bleeding. The ICU stay was significantly shorter in the low-dose group (8.4 vs 13.7 h, P = 0.020), less dependent on oxygen on the first postoperative day (78 vs 97%, P = 0.034), better mobilized (89 vs 59%, P = 0.006) and had less pain (visual analogue scale 2.0 vs 3.5, P = 0.019) compared with the control group.

Conclusions: The use of a mini-CPB system combined with a low dose of heparin reduced the need for blood transfusions and may facilitate the faster mobilization of the patients.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Blood Transfusion
  • Cardiopulmonary Bypass / adverse effects
  • Cardiopulmonary Bypass / instrumentation*
  • Coated Materials, Biocompatible*
  • Cognition
  • Coronary Artery Bypass / adverse effects
  • Coronary Artery Bypass / instrumentation*
  • Elective Surgical Procedures
  • Equipment Design
  • Female
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Heparin Antagonists / therapeutic use
  • Humans
  • Intensive Care Units
  • Length of Stay
  • Male
  • Middle Aged
  • Mobility Limitation
  • Oxygen Inhalation Therapy
  • Pain, Postoperative / etiology
  • Pain, Postoperative / therapy
  • Postoperative Hemorrhage / etiology
  • Postoperative Hemorrhage / therapy
  • Prospective Studies
  • Protamines / therapeutic use
  • Reoperation
  • Respiration, Artificial
  • Sweden
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Coated Materials, Biocompatible
  • Heparin Antagonists
  • Protamines
  • Heparin